{
  "docId": "019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "docSlug": "7c032e01619eda769cbeaf2bcfe382bc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 110 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 45,
  "pageCount": 110,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a simple bulleted list to convey management philosophy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de06f-52ef-7226-b4e8-f3f08eb88a26/45",
  "deckHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "deckJsonHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26.json",
  "deckAnchorHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Small corporate function / extremely limited overhead\nManage strategy, capital allocation, legal and financial controls\nZero-base all SG&A categories\nNo pre-set percentages of revenue or annual budgets\nExpect industry-leading employee productivity\nLow gross-margin mindset in a high gross-margin business",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ff33f93-2b78-4d20-8877-56f72f025908",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.75,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Culture of Cost Control and Productivity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d69a8442-ce04-49dc-86ad-0ccb03f00b64",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "42f5949e-1a00-4165-9c2c-b354e4153dc6",
      "evidence": "list/bullet: Small corporate function / extremely limited overhead Manage strategy, capital allocation, legal and financial controls Zero-base all SG&A categories No pre-set percentages of revenue or annual budgets Expec",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "zero-based-budgeting",
      "slug": null,
      "matchId": "5185ee89-7d8a-4ce5-91d9-00b76913fc7a",
      "evidence": "Zero-base all SG&A categories",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 50,
      "from": 40,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3fdb7ddf-ff36-442b-a6da-1c201a07a6a6",
      "evidence": "Discussion of traditional pharma R&D model and Valeant's advantages",
      "position": 1,
      "objective": "Highlighting the cost of inaction in traditional pharma R&D",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}